Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 4Terminated 2Recruiting 2

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Melanoma 49Breast Neoplasms 47Neoplasms 39Leukemia, Lymphocytic, Chronic, B-Cell 37Carcinoma, Non-Small-Cell Lung 36Neoplasm Metastasis 29Lymphoma, Large B-Cell, Diffuse 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Brain Neoplasms 24Lymphoma, Follicular 23Lung Neoplasms 23Colonic Neoplasms 23Rectal Neoplasms 22Carcinoma, Renal Cell 22Lymphoma, Non-Hodgkin 21Prostatic Neoplasms 20Glioblastoma 20Leukemia, Myeloid, Acute 19Kidney Neoplasms 19Pancreatic Neoplasms 18Lymphoma, B-Cell, Marginal Zone 18Lymphoma, Mantle-Cell 17Gliosarcoma 17Burkitt Lymphoma 17Sarcoma 16Multiple Myeloma 16Waldenstrom Macroglobulinemia 15Ovarian Neoplasms 15Esophageal Neoplasms 15Lymphoma 14

Interventions

ruxolitinib 1denileukin diftitox 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × NIH × Leukemia-Lymphoma, Adult T-Cell × Clear all
NCT01712659 2023-01-10

Ruxolitinib for Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
19 enrolled 17 charts
LymphoidOther hematologic neoplasm

Leukemia, T-Cell, Leukemia-Lymphoma, Adult T-Cell

NCT00117845 2019-11-19

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
17 enrolled 9 charts
LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡